Senseonics (NYSE:SENS) Given Buy Rating at HC Wainwright

Senseonics (NYSE:SENS - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $2.00 price target on the stock. HC Wainwright's target price indicates a potential upside of 209.36% from the stock's current price.

Separately, StockNews.com initiated coverage on Senseonics in a research note on Thursday, December 26th. They set a "sell" rating for the company.

Senseonics Stock Performance

Shares of Senseonics stock traded up $0.03 during trading hours on Wednesday, hitting $0.65. 11,502,141 shares of the company were exchanged, compared to its average volume of 14,658,552. Senseonics has a 1 year low of $0.25 and a 1 year high of $1.40. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The business has a 50-day moving average of $0.86 and a 200-day moving average of $0.54. The stock has a market capitalization of $384.88 million, a price-to-earnings ratio of -4.97 and a beta of 1.17.

Senseonics (NYSE:SENS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period in the previous year, the firm posted ($0.07) EPS. As a group, analysts expect that Senseonics will post -0.14 EPS for the current fiscal year.

Remove Ads

Insiders Place Their Bets

In other Senseonics news, CEO Timothy T. Goodnow acquired 315,000 shares of the business's stock in a transaction on Tuesday, December 10th. The stock was purchased at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the transaction, the chief executive officer now owns 11,310,355 shares of the company's stock, valued at $3,506,210.05. The trade was a 2.86 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Frederick T. Sullivan bought 124,933 shares of the stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now directly owns 2,478,844 shares of the company's stock, valued at $941,960.72. The trade was a 5.31 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Institutional Trading of Senseonics

Large investors have recently bought and sold shares of the company. FMR LLC grew its holdings in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after purchasing an additional 167,970 shares during the last quarter. Geode Capital Management LLC grew its holdings in Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock valued at $2,042,000 after purchasing an additional 179,103 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Senseonics in the third quarter valued at $117,000. Ridgecrest Wealth Partners LLC acquired a new stake in Senseonics in the fourth quarter valued at $60,000. Finally, Renaissance Technologies LLC acquired a new stake in Senseonics in the fourth quarter valued at $720,000. Institutional investors and hedge funds own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.